Comment: A commenter supported the proposal allowing ASM data to be submitted to CMS on behalf of ASM participants by a designated entity or individual, including third-party intermediaries as described in 512.720(a)
of this final rule, we solicited comments in an RFI for a potential policy wherein MVP Participants would select one quality measure from a subset of quality measures in each MVP, referred to as Core Elements and MVP Participants would select the other 3 required quality measures and would still have to meet existing MVP reporting requirements
In the CY 2023 PFS final rule, we discussed that many commenters supported our proposed delayed implementation, and many commenters expressed concerns with the redistributive impacts of the implementation of the 2017-based MEI in PFS ratesetting
Solutions: Extend trial to 6 months before concluding inefficacy (some benefits take longer), increase dosing within safe ranges if using lower end, switch peptides (try Cerebrolysin if using BPC-157, or vice versa), add comprehensive eye exam to rule out progression versus peptide failure, consider peptides preventing worsening rather than producing improvement, discontinue if truly no benefit after 6 months rigorous trial
The protocols raise many issues that are subject to change as new data emerge
Final Takeaway Peptide therapy is an exciting tool in modern medicine and wellness but it works best when paired with expert oversight, proper testing, and a personalized plan
